Carisma grants retention options: 125K shares CEO, 85K each CFO/CSO, vesting over 2 years

Carisma Therapeutics Inc.

CEO Steven Kelly receives option for 125,000 shares; CFO Richard Morris and CSO Michael Klichinsky each get 85,000 shares.
Exercise price equals closing price on June 17, 2024 grant date; options vest in two equal installments on first and second anniversaries.
Grants approved by Compensation Committee to incentivize retention during implementation of revised operating plan.
Company intends to make additional retention grants to other employees under the same plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.